Rocket Pharmaceuticals has signed an equity sales agreement with Cantor Fitzgerald & Co for an At-the-Market offering programme worth up to $100 million, according to a filing with the US Securities and Exchange Commission. The agreement allows the clinical-stage biotechnology company to issue and sell common stock to Cantor Fitzgerald based on market conditions. The ATM mechanism enables listed companies to raise capital in batches according to funding needs, helping optimise financing timing whilst reducing stock price impact. The financing will support Rocket Pharmaceuticals' development of gene therapies for rare diseases. Details of the agreement were filed via Form 8-K with the SEC.

Rocket Pharmaceuticals (RCKT) launches $100M at-the-market stock offering with Cantor. Filing Impact (Moderate) Filing Sentiment Rhea-AI Filing summary. Rocket Pharmaceuticals entered into a new sales agreement with Cantor Fitzgerald & Co. to establish an at-the-market stock offering program. Under this arrangement, the company may, at its discretion, sell shares of its common stock with an aggregate offering price of up to $100,000,000 through Cantor as sales agent. The shares will be issued under an existing shelf registration statement on Form S-3, supported by a prospectus supplement filed the same day. Cantor will sell the shares in transactions deemed at-the-market on Nasdaq, earning a cash commission of up to 3.0% of gross proceeds. Rocket can suspend or terminate sales at any time, and the program ends once all shares are sold or the agreement is otherwise terminated. In connection with this new arrangement, Rocket terminated its prior at-the-market sales agreement with Cowen and Company, LLC. Legal opinions and the full sales agreement are filed as exhibits, providing the formal framework for potential future equity issuance. 03/10/2026 - 05:24 PM Faq. What did Rocket Pharmaceuticals (RCKT) announce in this 8-K filing? Rocket Pharmaceuticals established a new at-the-market stock offering program with Cantor Fitzgerald, allowing it to sell up to $100,000,000 of common stock over time, using its existing Form S-3 shelf registration and a new prospectus supplement. How much stock can Rocket Pharmaceuticals (RCKT) sell under the new at-the-market program? Rocket Pharmaceuticals may sell common stock with an aggregate offering price of up to $100,000,000. Sales will occur from time to time at the company's discretion through Cantor Fitzgerald & Co. as sales agent under the sales agreement. Who is the sales agent for Rocket Pharmaceuticals' new at-the-market offering? Cantor Fitzgerald & Co. will act as sales agent for Rocket Pharmaceuticals. It will use commercially reasonable efforts to sell shares in at-the-market transactions on Nasdaq or other markets, consistent with its normal trading and sales practices and applicable regulations. What commission will Cantor Fitzgerald receive in Rocket Pharmaceuticals' ATM program? Cantor Fitzgerald is entitled to a cash commission of up to 3.0% of gross proceeds from any Rocket Pharmaceuticals common stock sold under the at-the-market program, plus reimbursement of certain expenses and customary indemnification and contribution protections. What happened to Rocket Pharmaceuticals' prior at-the-market agreement? Upon entering the new sales agreement with Cantor Fitzgerald, Rocket Pharmaceuticals terminated its prior at-the-market sales agreement with Cowen and Company, LLC, which had allowed Cowen to act as agent for periodic common stock sales. Under which registration statement will Rocket Pharmaceuticals' ATM shares be issued? The shares sold through the at-the-market program will be issued under Rocket Pharmaceuticals' shelf registration statement on Form S-3, File No. 333-293925, with a related prospectus supplement filed to cover sales under the Cantor sales agreement. Filing exhibits & attachments. 5 documents Agreements & contracts.

Rocket Pharmaceuticals reported a fourth-quarter loss of 38 cents per share, narrower than the Zacks Consensus Estimate of a loss of 42 cents and improved from a loss of 62 cents in the year-ago quarter. The company recorded no revenues as it has no marketed products. Research and development expenses fell 21.6% year over year to $29.3 million, reflecting disciplined spending following recent restructuring. The company held $188.9 million in cash and investments as of 31 December 2025, expected to fund operations into the second quarter of 2027. The FDA is reviewing Rocket's biologics licence application for gene therapy Kresladi to treat severe leukocyte adhesion deficiency-I, with a decision expected on 28 March 2026.